The ENVISAGE-TAVI AF trial demonstrated that Edoxaban’s non-inferiority to warfarin with regards to myocardial infarction (MI), ischaemic stroke, systemic thromboembolism, and valve thrombosis, in participants…
View More Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF
By Ahmed El-Medany As usual, there were a multitude of fascinating trials presented at the Hot Line session at the ESC Congress 2021. Professor Axel…
View More Highlights from Day 1 of the ESC congress – SMART-MI
By Giovanni Occhipinti, Chiara Bucciarelli-Ducci & Davide Capodanno When acute myocardial injury is found in a clinical setting suggestive of myocardial ischaemia, the event is…
View More Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA)
By Ahmed El-Medany Longer door-to-balloon times and higher percutaneous coronary intervention (PCI) failure rate were observed in a multicentre study by Faroux et al. 118…
View More STEMI after TAVR associated with poorer outcomes.
By Ahmed El-Medany In a large retrospective study by Venetsanos et al, researchers analysed 37,990 patients from the SWEDEHEART registry with myocardial infarction (MI) who…
View More Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction